Circulating Immunes Cells, Cytokines and Brain Radiotherapy
Recruiting
N/AInterventional Study
Head and Neck Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
40 (estimated)
Sponsor
Centre Francois Baclesse · Other
Who this trial is looking for
This trial is looking for patients with head and neck cancer who have had surgery. Participants will receive either proton or carbon therapy after their surgery.
Are You a Good Fit for This Trial?
You may be able to join if
I am over 18 years old
I have head and neck cancer
I have had surgery to remove my tumor
I have no visible tumor left after surgery
I am set to receive at least 54 Gy of radiation
I am part of a social security scheme
I will sign consent before joining the study
You may not be able to join if
I have visible tumor left after surgery
I have had another cancer in the past 5 years (except certain skin or cervical cancers)
I have had radiation therapy before
I am currently receiving chemotherapy or certain other cancer treatments with radiation
I have been on long-term immunosuppressive treatments
I am a prisoner or under guardianship
I can't participate in the study for personal reasons
I am pregnant or breastfeeding
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Patients with malignant tumours of the cephalic pole have a poor prognosis, despite a wide range of treatments. prognosis despite a large therapeutic arsenal. Among this arsenal, radiotherapy (RT) is one of the standard treatments for these tumours. However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic However, this treatment can cause damage t…
Patients with malignant tumours of the cephalic pole have a poor prognosis, despite a wide range of treatments. prognosis despite a large therapeutic arsenal. Among this arsenal, radiotherapy (RT) is one of the standard treatments for these tumours. However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic tissue and can promote pro-tumour inflammation.
In these circumstances, hadrontherapy, which uses charged heavy particles, such as protons or carbon ions, is the preferred treatment. protons or carbon ions, seems more appropriate for the treatment of these tumours. However, although inflammation plays a major role in tumour development and tumour development and therapeutic response, few studies have evaluated the immune response response after proton therapy (PT) and carbon therapy (CT). The objective of this project is to study the effect of hadrontherapy on resident/circulating inflammation after brain irradiation. brain irradiation. In a first step, the impact of different PT and CT TEL on macrophages (M\Ф), the most abundant immune cells in malignant solid tumours, will be evaluated in vitro. malignant solid tumours, will be evaluated in vitro. In a second step, the evolution of circulating leukocytes after brain irradiation with X-rays or protons will be studied in vivo in rodents and patients. rodent and patient. In this project, we propose to study for the first time the inflammatory response after hadrontherapy in the context of a cephalic tumour. cephalic tumour. These results will allow a better understanding of the biological response response following PT and CT with the aim of optimising RT and potentially and potentially translate these data to the clinic.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Patients \> 18 years
* Head and neck cancer: (upper aerodigestive tract, cavum, facial sinus, skull base, brain) operated
* Surgery for complete tumour resection or with microscopic residue R1
* All possible histologies: squamous cell carcinoma, undifferentiated carcinoma of t…
Inclusion Criteria:
* Patients \> 18 years
* Head and neck cancer: (upper aerodigestive tract, cavum, facial sinus, skull base, brain) operated
* Surgery for complete tumour resection or with microscopic residue R1
* All possible histologies: squamous cell carcinoma, undifferentiated carcinoma of the nasopharyngeal type (UCNT), adenocarcinoma, adenoid cystic carcinoma, chordoma, chondrosarcoma,meningioma other tumours
* Patients undergoing exclusive postoperative radiotherapy with a minimum total dose of 54 Gy of X-ray photon radiation or equivalent proton radiation.
* Patient affiliated to a social security scheme
* Signature of the informed consent before any specific procedure related to the study
Exclusion Criteria:
* Macroscopic postoperative tumour residue R2
* Previous cancer within 5 years (except treated basal cell skin carcinoma and treated cervical cancer).
* Previous radiotherapy (except brachytherapy of the cervix or prostate)
* Chemotherapy or other systemic oncological treatment (cetuximab) concomitant with radiotherapy
* Long-term immunosuppressive or corticosteroid therapy
* Patient deprived of liberty or under guardianship, protected adult
* Patient unable to undergo trial monitoring for geographical, social or psychopathological reasons
* Pregnant or breastfeeding woman
* Emergency situations
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.